Waitaki Biosciences CEO Craig McIntosh, noted, “Waitaki’s product range has traditionally been in the area of bone and joint health and inflammation. The addition of these new ingredients widens the net where our products have application, providing our customers with a more complete range of healthcare solutions. Given increased focus on clean ingredients in the U.S., Europe and Asia, those sourced from New Zealand’s wholesome environment are just what consumers are seeking.”
 
New Zealand-grown fruit varieties in particular, from which ActiPhen and CassiPure are derived, have a number of advantages over their global counterparts, according to the company. This is as a direct result of the unique New Zealand growing environment, which includes strict non-GMO policies, clean, environmentally sustainable growing practices and, as a consequence of the seasonal hole in the ozone layer, higher than normal levels of protective phytonutrients.
 
The successful installation and commissioning of a new 1-ton freeze dryer further cements Waitaki Biosciences’ position as one of New Zealand’s leading manufacturers of high value nutraceutical ingredients. The new freeze dryer adds an additional 200 MT of freeze dried material to annual production.
 
Simultaneously the company has been building a sophisticated new custom-designed solvent extraction facility, a project, which has seen significant investment over the past two years. The solvent extraction facility effectively creates an entirely new business for the company, adding high value marine and botanical extracts to its traditional product portfolio. 
 
For more information: www.waitakibio.com